Noninvasive liver fibrosis index changes during chemotherapy: Marker for oxaliplatin-induced hepatic sinusoidal obstruction syndrome.

9617 Background: Even though oxaliplatin (OXA) could induce hepatic sinusoidal obstruction syndrome (SOS), OXA-based regimes are still standard treatment for patients with colorectal (CRC) and advanced gastric cancer (AGC). The aim of the study was to evaluate the utility of non-invasive liver fibrosis index (NIFI) for monitoring OXA-induced hepatic SOS. Methods: From February 2004 to December 2013 patients with CRC or AGC who received OXA-based chemotherapy (CTx) were identified in the institutional electronic patient database. Liver fibrosis were evaluated before and after the OXA exposure with splenic volume index (SVI) and 4 different NIFIs: age-platelet index (API), AST to platelet ratio index (APRI), platelet to spleen ratio (PSR), Fibrosis-4 score (FIB-4). Adjusted odd ratio (aOR) with 95% confidence intervals (CI) were analyzed to evaluate risk after matching age, body mass index, cancer type, stage, previous chemotherapy cycle. Results: A total of 288 patients (pts) were eligible for evaluation: ...